Company Overview of 3SBio Inc.
3SBio Inc., a biotechnology company, engages in the research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also markets Intefen, a recombinant interferon alpha-2a product to treat carcinoma and viral infectious diseases; Inleusin, a recombinant human interleukin-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused b...
No. 3 A1, Road 10
Shenyang Economy & Technology Development Zone
Founded in 1993
Key Executives for 3SBio Inc.
Vice President and Corporate Secretary
Compensation as of Fiscal Year 2014.
3SBio Inc. Key Developments
Selecta Biosciences Inc Enters into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout
Jun 17 14
Selecta Biosciences Inc. announced it has entered into an exclusive license with 3SBio for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to develop pegsiticase in patients with refractory and tophaceous gout and apply its immunomodulatory Synthetic Vaccine Particle (SVP) platform to optimize the safety and efficacy profile for patients at risk of immunogenicity. SEL-212 is a novel product that combines Selecta's proprietary SVP with 3SBio's pegsiticase and is designed to be the first non-immunogenic version of uricase. Selecta will work with 3SBio to advance pegsiticase-based therapeutics as potential treatments for refractory and tophaceous gout as well as tumor lysis syndrome, with the ultimate goal of expeditiously moving toward regulatory approvals. Selecta and 3SBio have agreed to work together to achieve clinical proof of concept for SEL-212 and pegsiticase in human clinical trials in their territories; Selecta's territory includes US and all of Europe. Proof-of-concept clinical studies are expected to be initiated in 2015. Additional terms of the exclusive license granted by 3SBio to Selecta are not being disclosed.
3SBio Inc. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 01:30 PM
May 1 14
3SBio Inc. Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 01:30 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China. Speakers: Bo Tan, Chief Financial Officer, Principal Accounting Officer and Member of Investment Committee.
3SBio Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 09:00 AM
Nov 1 13
3SBio Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 09:00 AM. Venue: China National Convention Center, No.7 Tianchen East Road, Chaoyang District, Beijing 100105, China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|